Sema4 Holdings Corp. The company is headquartered in Stamford, Connecticut.
| Revenue (TTM) | $454.43M |
| Gross Profit (TTM) | $315.30M |
| EBITDA | $-33.70M |
| Operating Margin | -15.20% |
| Return on Equity | -40.80% |
| Return on Assets | -7.89% |
| Revenue/Share (TTM) | $15.55 |
| Book Value | $8.19 |
| Price-to-Book | 10.67 |
| Price-to-Sales (TTM) | 5.64 |
| EV/Revenue | 5.81 |
| EV/EBITDA | 161.17 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 11.40% |
| Shares Outstanding | $29.82M |
| Float | $20.46M |
| % Insiders | 12.25% |
| % Institutions | 107.60% |
Volatility is currently contracting
GeneDx Holdings Corp. (WGS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
GeneDx shows early signs of operational recovery, with Q2 revenue and margins exceeding expectations and testing volumes up 32%. Reimbursement rates have stabilized, and management expects meaningful improvements in Q4 and a stronger recovery in 2027. Valuation remains attractive, with a Buy rating maintained. Upside potential exists if reimbursement and growth targets are met.
GeneDx Holdings Corp. (WGS) Q2 2026 Earnings Call Transcript
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) today reported its financial and operational results for the second quarter of 2026.
New York, New York--(Newsfile Corp. - August 3, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against GeneDx Holdings Corp. (NASDAQ: WGS) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired GeneDx securities between April 16, 2025 and May 4, 2026, both dates inclusive (the "Class Period").
LOS ANGELES, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against GeneDx Holdings Corp. (“GeneDx” or “the Company”) (NASDAQ: WGS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of WGS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.
LOS ANGELES, Aug. 3, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against GeneDx Holdings Corp. ("GeneDx" or "the Company") (NASDAQ: WGS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of WGS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.
LOS ANGELES, Aug. 3, 2026 /PRNewswire/ -- Schall Brown & Schwartz LLP, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against GeneDx Holdings Corp. ("GeneDx" or "the Company") (NASDAQ: WGS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. If you purchased GeneDx Holdings Corp. securities during the Class Period you may be entitled to compensation without payment of any out-of-pocket fees or costs.
SAN FRANCISCO, July 31, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in GeneDx Holdings Corp. (NASDAQ: WGS) that a securities fraud class action lawsuit has been filed, and the firm is actively urging investors with substantial losses contact the firm now. The upcoming lead plaintiff deadline is August 3, 2026.
New York, New York--(Newsfile Corp. - July 31, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of GeneDx Holdings Corp. (NASDAQ: WGS) between April 16, 2025 and May 4, 2026, inclusive (the "Class Period"), of the important August 3, 2026 lead plaintiff deadline. SO WHAT: If you purchased GeneDx common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on WGS and any ticker you trade — then tracks every position and per-strategy win rate.
